Researchers excited about the identification of a brain region that responds to more than one type of anti-psychotic drug, as the feel that it could expand the options for controlling schizophrenia.
The researchers say that their findings are the first to illustrate that the orbitofrontal cortex-a brain region responsible for cognitive activity such as decision making-could be a promising target for developing future antipsychotic drugs, even those that have very different mechanisms of action.
Bita Moghaddam, a professor in the Department of Neuroscience in Pitt's School of Arts and Sciences, says that the study has shown that schizophrenia-like activity in the orbitofrontal cortex could be triggered by the two different neurotransmitters linked to schizophrenia: dopamine and glutamate.
"The orbitofrontal cortex is an area that's been somewhat neglected in schizophrenia research. This study should encourage researchers to focus on this brain region in imaging and other human studies, and also to use as a model for developing antipsychotic drugs," Moghaddam said.
"Schizophrenia appears to be caused by very diverse and sometimes rare genetic mutations. Diverse mutations can end up causing the same disease if they disrupt the function of a common group of neurons or networks of neurons. We think that the key to understanding the pathophysiology of schizophrenia and finding better treatments is to identify these networks. This data suggests that the orbitofrontal cortex may be a critical component in networks affected by schizophrenia," the researcher added.
Working with UPMC neurology resident Houman Homayoun, Moghaddam first established that both dopamine and glutamate could produce schizophrenia-like symptoms in the orbitofrontal cortex.
The researchers said that previous studies had already shown that under-functioning glutamate receptors known as NMDA receptors could produce schizophrenia-like symptoms.
In the current study, according to the researchers, it was found that stunting the NMDA receptors could lead to schizophrenia-like effects in the orbitofrontal cortex.
The researchers also used a dose of amphetamine to simulate dopamine-related schizophrenia symptoms in the orbitofrontal cortex, as schizophrenia is often linked to an excess of dopamine in the brain.
Moghaddam and Homayoun then tested the currently prescribed medication-a treatment developed more than 50 years ago that targets neural receptors of dopamine-and new experimental drugs that work on the glutamate system.
They observed that both medications normalized brain activity.
The study has been published in the online edition of the journal Proceedings of National Academy of Sciences.